Excerpts from latest analyst reports.....

Maybank KE says 'big overhang removed' from China Minzhong

Analyst: WEI Bin

minzhong_mushroom
China Minzhong is a leading integrated vegetable processor in the PRC and one of the few with its own processing capabilities as well as cultivation bases. Photo: Company



Olympus Capital, a private equity fund, has sold its entire stake of 57m shares in China Minzhong through a private placement last Thursday at SGD0.80 per share.

In our view, this placement is a positive for Minzhong as it removes a long-term share overhang on the company without adding too much selling pressure in the open market.  

Ø  In a show of solidarity, management took advantage of the vendor share placement to increase personal stakeholdings. This clearly signals management’s confidence in the company’s fundamentals and the attractiveness of its share price.

Ø  We continue to like Minzhong for its growth prospects. We are looking at an average of 15% EPS growth for the next three years. As it stands, Minzhong’s share price is deeply undervalued at the current 2.9x FY13F PER. Reiterate BUY with the target price unchanged at SGD1.16.

minzhong_maybankke12.12

 

Recent story:  CHINA MINZHONG gets new big shareholder, AUSGROUP price is up, JEL's ex-CEO sells down



DBS Vickers highlights Cordlife's "stable recurring income"

Analysts: LING Lee Keng & Andy SIM

• Larger of only two private cord blood banks in Singapore; among the top 3 in Hong Kong
• Increasing penetration rate and awareness of cord blood banking to drive growth
• Stable recurring income; potential acquisitions in Indonesia, India and Philippines
• Fair value of S$0.65 offers 21% potential upside

cordlife_dbs12.12

Fair value S$0.65. The stock current trades at 14.0x FY13F PE.

We believe a target PE of 16x based on a slight (<10%) discount to blended forward PE of its peers is reasonable, given its shorter trading history. This translates to a fair value of S$0.65, which offers potential upside of 20% from current share price.

Key risks include reputational risk. Any problem with the quality of its cord blood banking services will be extremely detrimental to the Group.

Recent story: GLOBAL PREMIUM HOTELS, AURIC PACIFIC, CORDLIFE: What analysts now say....

You may also be interested in:


Comments  

#3 Rock1 2012-12-11 07:51
Cordlife enjoys recurring profit but China Minzhong profit is uncertain.
#2 Lazy investor 2012-12-10 18:09
I compare Minzhong and Cordlife. Why is Cordlife enjoying such high price-earnings ratio of >12X? Partly it's because it is net cash and it has strong real cashflow! But I wouldn't buy Cordlife at 55-cent level as it's not cheap
#1 Lazy investor 2012-12-10 18:07
On a price-earnings basis, China Minzhong is really cheap at 3X. The stumbling block is the leverage -- it's got RMB302 m cash versus nearly RMB700 m bank borrowings. It looks like the cashflow will improve over the next 2 years according to the DBS projection. Well, it 's not a short wait.

You have no rights to post comments

 

We have 1450 guests and no members online

rss_2 NextInsight - Latest News